Wall Street equity research analysts tracking CRISPR Therapeutics AG (CRSP) maintain a median twelve-month consensus price target hovering around $80 per share, with individual institutional forecasts ranging from a low of $44 up to a high of $291. Quantitative long-term projection models estimate that trading values could approach the $65 to $93 range heading deeper into 2027, driven by accelerating Casgevy adoption and clinical pipeline advancements.